Quartz 4

H4 Blocker Compounds

3 min read

H4 Blocker Compounds

Background

H4 Receptor are expressed on mast cells themselves — activation creates an autocrine amplification loop where histamine drives further Degranulation. H4 blockade interrupts this loop. Distinct from H1/H2 blockade which addresses downstream receptor effects.

H4 antagonists failed in clinical trials not because the mechanism is wrong but because of indication mismatch — tested in atopic dermatitis and asthma where H4 is one of many drivers, not the central mechanism. Analogous to using a renin inhibitor in a hypertensive population where only 30% have renin-driven disease.

MCAS is a better indication because mast cells are the primary pathology, not a contributing factor.

Compounds That Reached Human Trials

ZPL-3893888 (Ziarco → Pfizer)

  • Phase 2 for atopic dermatitis
  • Ziarco acquired by Pfizer 2017
  • No Phase 3 published — quietly shelved
  • No agranulocytosis signal observed
  • Most promising compound in class for safety profile
  • Current status: shelved at Pfizer, no active development known

JNJ-39758979 (Janssen)

  • Phase 2 for atopic dermatitis and chronic pruritus
  • Stopped early due to agranulocytosis in two subjects
  • Serious signal — agranulocytosis (dangerously low neutrophil count, <500 cells/µL) is rare enough in general population that two cases in a single trial is statistically meaningful
  • Whether compound-specific metabolite issue or class effect remains unresolved
  • Absence of signal in ZPL-3893888 suggests compound-specific, not class effect
  • H4 receptors expressed on some hematopoietic cells — class effect concern not paranoid but currently unsupported by cross-compound data

Toreforant / RO6889678 (Roche)

  • Tested in rheumatoid arthritis and asthma
  • Did not meet endpoints, discontinued

UR-63325

  • Earlier stage, limited published data

Current Availability

No H4-selective blocker is approved or commercially available. All remain research compounds.

Cetirizine (H1 blocker) has some H4 receptor affinity — not clean H4 blockade but partial coverage. Already accessible OTC.

The ZPL-3893888 Case

The commercial argument for Pfizer pursuing MCAS indication:

  • 8% symptomatic population conservatively = 26M US patients
  • Chronic condition requiring ongoing medication
  • No current targeted therapy approved for MCAS
  • Orphan Drug Designation potentially applicable depending on strict vs. broad diagnostic criteria
  • Existing Phase 2 safety data — not starting from zero
  • Atopic dermatitis failure was endpoint/indication mismatch, not mechanism failure
  • JNJ safety signal does not apply (no agranulocytosis in ZPL trials)

Pathway: TMS (The Mast Cell Disease Society) or Mastocytosis Society as intermediary with scientific credibility. Frame as commercial opportunity, not patient plea. FDA Orphan Drug Designation changes the economics significantly — 7 years market exclusivity, trial cost tax credits, expedited review.

Graph View

Backlinks